

Figure S1. Characterize BMMSCs isolated from healthy donors' bone marrow(a) The potential of adipogenic, osteogenic, and cartilage differentiation of BMMSCswas verified. (b) Expression of CD73, CD90, and CD105 and lack of CD14, CD34,

and CD45 were assessed by flow cytometry.



Figure S2. The caspase 3 activity of *Crif1*- deficient BMMSCs (Crif1-SI) and control cells (Con-EV) at 48 h after irradiation was examined. BMMSCs transfected with Crif1 shRNA are referred as Crif1-SI, and BMMSCs transfected with empty control vectors are referred as Con-EV. The experiments were performed in triplicate in the same cell line, and representative images are shown. Data represent the mean \pm SEM. * p < 0.05, ** p < 0.01, ns (not significant), compared to the control





9 Gy - 72 h



Figure S3. The level of cell senescence was examined when activating NRF2 through *tert*-butylhydroquinone (t-BHQ) or *Nrf2* overexpression vectors in BMMSCs before irradiation. (a) Western blot results of NRF2 in *Crif1*-deficient BMMSCs (Crif1-SI) and control cells (Con-EV) treated with 100 mmol/L t-BHQ for 12 h, or 5 μ g *Nrf2* overexpression vectors (Nrf2-OE) or nonspecific control (Con-NS) for 48 h. (b)Senescence was examined in *Crif1*-deficient BMMSCs (Crif1-SI) and control cells (Con-EV) 72 h after 9 Gy irradiation using SA-β-Gal staining (up panel) and

quantification (down panel). The cells were treated with 100 mmol/L t-BHQ for 12 h or 5 µg *Nrf2* overexpression vectors (Nrf2-OE) or non-specificity control (Con-NS) for 48 h before irradiation. The experiments were performed in triplicate in the same cell line, and representative images are shown. Data represent the mean \pm SEM. * *p* < 0.05, ** *p* < 0.01, ns(not significant), compared to the control

Table S1. Interference sequences for shCrif1

	shCrif1		
Forward	GATCCAAGAACGCGAATGGTACCCGATTCAAGAGATCGGGTAC-		
	CATTCGCGTTCTTTTTTG		
Reverse	AATTCAAAAAAAGAACGCGAATGGTACCCGATCTCTTGAATCG-		
	GGTACCATTCGCGTTCTTG		

Table S2. Sequences of amplification primers used for *Crif1*overexpression

	Crif1 overexpression	
Forward	ATAGGATCCACCATGGCGGCGTCCGTGCGA	
Reverse	CGCCTCGAGCCTCAGGAGCTGGGTGCCC	

Table S3. Sequences of forward and reverse primers used for qPCR

Gene	Forward	Reverse
Cuifl	GGCCCAGGCTGACAAGGAG-	GCGCCTCCTTCTTCCGTT-
Criji	AG	TCTGT
Nuer?	ACACGGTCCACAGCTCATC-	AGCCACTTTATTCTTACC-
INFJ2		ССТССТА
Uol	AAGACTGCGTTCCTGCTCA-	AAAGCCCTACAGCAACTG-
ПОТ	AC	TCG
Cala	GCAAACCATCCTGACTACAA-	GCTGGCTGAGAGGCATG-
0010	GCAAG	GTAC
Catl	GGGGCACTGCTCACCTGTCT-	CCCCAGCAGCTCCCACC-
Ggil	GTC	AC
<i>B</i> actin	ACCCCGTGCTGCTGA CCGAG	TCCCGGCCAGCCAGGTC-
p-actin		CA